Company profile for Travere Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

At Travere Therapeutics, our mission is to identify, develop and deliver life-changing therapies to people living with rare disease. At Travere Therapeutics, we come to work every day to make a difference in the lives of the patients we serve. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therap...
At Travere Therapeutics, our mission is to identify, develop and deliver life-changing therapies to people living with rare disease. At Travere Therapeutics, we come to work every day to make a difference in the lives of the patients we serve. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. We come together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
3721 Valley Centre Drive, Suite 200 San Diego, CA 92130
Telephone
Telephone
888-969-7879 (RTRX)
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251211779425/en/Travere-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4

BUSINESSWIRE
11 Dec 2025

https://www.businesswire.com/news/home/20251110582660/en/Travere-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4

BUSINESS WIRE
10 Nov 2025

https://www.businesswire.com/news/home/20251106843166/en/Travere-Therapeutics-Announces-Late-Breaking-Data-from-Phase-3-DUPLEX-Study-of-FILSPARI-in-FSGS-Presented-at-the-American-Society-of-Nephrology-ASN-Kidney-Week-2025

BUSINESS WIRE
06 Nov 2025

https://www.businesswire.com/news/home/20251104923461/en/Travere-Therapeutics-to-Participate-at-Upcoming-Investor-Conferences

BUSINESSWIRE
04 Nov 2025

https://www.businesswire.com/news/home/20251030466173/en/Travere-Therapeutics-Reports-Third-Quarter-2025-Financial-Results

BUSINESSWIRE
30 Oct 2025

https://www.businesswire.com/news/home/20251023110159/en/Travere-Therapeutics-to-Report-Third-Quarter-2025-Financial-Results

BUSINESSWIRE
23 Oct 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty